Newall AT, Chen C, Wood JG, Stockwell MS. Within-season influenza vaccine waning suggests potential net benefits to delayed vaccination in older adults in the United States. Vaccine. 2018 Aug 23. pii: S0264-410X(18)31114-9
BACKGROUND:
There is growing evidence that there is within (intra-) season waning of influenza vaccine protection in older adults, suggesting there may be a benefit to giving influenza vaccine closer to the time of increased infection risk. We aimed to quantitatively evaluate the impact of modifying the timing of influenza vaccination in U.S. older adults.
METHODS:
Using historical data (2010/2011-2015/2016, inclusive) on influenza activity and vaccine uptake, we explore the optimal time to begin vaccinating older adults (≥65?years) in the U.S. to maximize prevention of influenza. We modelled the effect of changing the timing of vaccination by estimating the percentage change to the current disease burden and used this to calculate the estimated optimal week to begin vaccination in the U.S.
RESULTS:
When we assumed a relatively slower waning protection rate (over 52?weeks), the estimated optimal time to begin vaccinating those aged?≥65?years varied between mid-August (week 34, 2012-2013) and mid-late October (week 43, 2011-2012) depending on the season, resulting in 0.44% and 5.11% of the current disease burden prevented respectively. Under faster waning (over 26?weeks), the estimated optimal week varied between early September (week 37, 2012-2013) and mid-November (week 47, 2011-2012), resulting in 3.69% and 11.97% of the current disease burden prevented respectively.
CONCLUSIONS:
While it is difficult to determine the ideal time to start to vaccinate due to substantial variation in timing of individual seasons, we found that there are potentially substantial benefits to minimizing the time between vaccination and influenza activity in U.S. older adults. Modest delays in immunization were beneficial in the seasons we evaluated. If further evidence suggests fast waning, longer delays may be warrant as in these scenarios the timing of the current vaccination was often very suboptimal.
There is growing evidence that there is within (intra-) season waning of influenza vaccine protection in older adults, suggesting there may be a benefit to giving influenza vaccine closer to the time of increased infection risk. We aimed to quantitatively evaluate the impact of modifying the timing of influenza vaccination in U.S. older adults.
METHODS:
Using historical data (2010/2011-2015/2016, inclusive) on influenza activity and vaccine uptake, we explore the optimal time to begin vaccinating older adults (≥65?years) in the U.S. to maximize prevention of influenza. We modelled the effect of changing the timing of vaccination by estimating the percentage change to the current disease burden and used this to calculate the estimated optimal week to begin vaccination in the U.S.
RESULTS:
When we assumed a relatively slower waning protection rate (over 52?weeks), the estimated optimal time to begin vaccinating those aged?≥65?years varied between mid-August (week 34, 2012-2013) and mid-late October (week 43, 2011-2012) depending on the season, resulting in 0.44% and 5.11% of the current disease burden prevented respectively. Under faster waning (over 26?weeks), the estimated optimal week varied between early September (week 37, 2012-2013) and mid-November (week 47, 2011-2012), resulting in 3.69% and 11.97% of the current disease burden prevented respectively.
CONCLUSIONS:
While it is difficult to determine the ideal time to start to vaccinate due to substantial variation in timing of individual seasons, we found that there are potentially substantial benefits to minimizing the time between vaccination and influenza activity in U.S. older adults. Modest delays in immunization were beneficial in the seasons we evaluated. If further evidence suggests fast waning, longer delays may be warrant as in these scenarios the timing of the current vaccination was often very suboptimal.
See Also:
Latest articles in those days:
- T cell help is a limiting factor for rare anti-influenza memory B cells to reenter germinal centers and generate potent broadly neutralizing antibodies 2 days ago
- Wild birds drive the introduction, maintenance, and spread of H5N1 clade 2.3.4.4b high pathogenicity avian influenza viruses in Spain, 2021-2022 2 days ago
- [preprint]FluNexus: a versatile web platform for antigenic prediction and visualization of influenza A viruses 2 days ago
- Salpingitis and multiorgan lesions caused by highly pathogenic avian influenza A(H5N1) virus in a cat associated with consumption of recalled raw milk in California 2 days ago
- Detection of highly pathogenic avian influenza A(H5N1) virus 2.3.4.4b in alpacas 2 days ago
[Go Top] [Close Window]


